JP2015522573A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522573A5 JP2015522573A5 JP2015519000A JP2015519000A JP2015522573A5 JP 2015522573 A5 JP2015522573 A5 JP 2015522573A5 JP 2015519000 A JP2015519000 A JP 2015519000A JP 2015519000 A JP2015519000 A JP 2015519000A JP 2015522573 A5 JP2015522573 A5 JP 2015522573A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- composition according
- composition
- glp
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 17
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 8
- 208000008589 Obesity Diseases 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000036186 satiety Effects 0.000 claims 2
- 235000019627 satiety Nutrition 0.000 claims 2
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical group CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229950011186 semaglutide Drugs 0.000 claims 1
- 108010060325 semaglutide Proteins 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12174535.0 | 2012-07-01 | ||
| EP12174535 | 2012-07-01 | ||
| US201261694837P | 2012-08-30 | 2012-08-30 | |
| US61/694,837 | 2012-08-30 | ||
| US201261708162P | 2012-10-01 | 2012-10-01 | |
| EP12186781.6 | 2012-10-01 | ||
| US61/708,162 | 2012-10-01 | ||
| EP12186781 | 2012-10-01 | ||
| PCT/EP2013/063004 WO2014005858A1 (en) | 2012-07-01 | 2013-06-21 | Use of long-acting glp-1 peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522573A JP2015522573A (ja) | 2015-08-06 |
| JP2015522573A5 true JP2015522573A5 (enExample) | 2016-03-10 |
| JP6059802B2 JP6059802B2 (ja) | 2017-01-11 |
Family
ID=65858459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519000A Active JP6059802B2 (ja) | 2012-07-01 | 2013-06-21 | 長時間作用型ｇｌｐ−１ペプチドの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9764003B2 (enExample) |
| EP (3) | EP4406593A3 (enExample) |
| JP (1) | JP6059802B2 (enExample) |
| AU (3) | AU2013286177B2 (enExample) |
| BR (1) | BR112014032938A2 (enExample) |
| CA (1) | CA2877056A1 (enExample) |
| DK (1) | DK2866825T3 (enExample) |
| ES (2) | ES2796839T3 (enExample) |
| HR (2) | HRP20251088T1 (enExample) |
| HU (2) | HUE072859T2 (enExample) |
| MX (3) | MX366405B (enExample) |
| PL (2) | PL3689365T3 (enExample) |
| PT (1) | PT2866825T (enExample) |
| RS (2) | RS60432B1 (enExample) |
| RU (2) | RU2018117557A (enExample) |
| SI (1) | SI2866825T1 (enExample) |
| WO (1) | WO2014005858A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012080471A1 (en) | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| HUE031405T2 (en) | 2011-04-12 | 2017-07-28 | Novo Nordisk As | Double-acylated GLP-1 derivatives |
| MY171146A (en) | 2012-03-22 | 2019-09-27 | Novo Nordisk As | Compositions of glp-1 peptides and preparation thereof |
| US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
| SI2866825T1 (sl) | 2012-07-01 | 2020-07-31 | Novo Nordisk A/S | Uporaba dolgo delujočih peptidov GLP-1 |
| PT2991671T (pt) | 2013-05-02 | 2018-11-05 | Novo Nordisk As | Dosagem oral de compostos de glp-1 |
| CN110254223B (zh) * | 2014-10-16 | 2022-03-25 | 洋马动力科技有限公司 | 拖拉机 |
| GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
| DE102017106216A1 (de) * | 2017-03-22 | 2018-09-27 | Amw Gmbh | Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| CN120241968A (zh) * | 2017-10-12 | 2025-07-04 | 诺和诺德股份有限公司 | 用于药物治疗的司美鲁肽 |
| GB201720187D0 (en) * | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Novel Compounds |
| MA53076B1 (fr) | 2018-02-02 | 2023-11-30 | Novo Nordisk As | Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| US20210162013A1 (en) * | 2018-08-03 | 2021-06-03 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
| EP3930753A4 (en) * | 2019-02-26 | 2023-03-29 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR GLP1 RECEPTOR |
| MX2022004779A (es) * | 2019-11-06 | 2022-06-14 | Novo Nordisk As | Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia. |
| CN114901680B (zh) * | 2019-12-30 | 2024-09-27 | 甘李药业股份有限公司 | 长效glp-1化合物 |
| US20230093542A1 (en) * | 2020-02-18 | 2023-03-23 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| CN112768087A (zh) * | 2020-12-23 | 2021-05-07 | 吉林大学 | 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途 |
| US20240285729A1 (en) * | 2021-06-24 | 2024-08-29 | Gila Therapeutics, Inc. | Methods and kits for inducing satiety and treating metabolic disorders |
| US12514908B2 (en) | 2021-07-05 | 2026-01-06 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| MX2024003872A (es) | 2021-09-27 | 2024-04-19 | Terns Pharmaceuticals Inc | Acidos carboxilicos de benzimidazol como agonistas de glp-1r. |
| EP4422745A1 (en) | 2021-10-25 | 2024-09-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| JP2024544920A (ja) | 2021-11-10 | 2024-12-05 | アイ２オー セラピューティクス，インク． | イオン液体組成物 |
| CN114621339B (zh) * | 2021-12-28 | 2022-09-23 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
| MX2024010346A (es) | 2022-02-23 | 2024-08-30 | Terns Pharmaceuticals Inc | Compuestos como agonistas de glp-1r. |
| WO2023225370A1 (en) * | 2022-05-19 | 2023-11-23 | Vault Bioventures, Inc. | Obesity treatment and prevention methods |
| CN121001710A (zh) | 2022-12-30 | 2025-11-21 | 阿尔吉法玛公司 | 提高口服多肽治疗剂的全身生物利用度的组合物和方法 |
| TW202506131A (zh) | 2023-04-07 | 2025-02-16 | 美商拓臻製藥公司 | ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法 |
| WO2025024455A1 (en) | 2023-07-24 | 2025-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for delivery of therapeutic peptides |
| WO2025165146A1 (ko) * | 2024-01-29 | 2025-08-07 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| CN118845644B (zh) * | 2024-09-27 | 2025-01-17 | 杭州信海医药科技有限公司 | 一种司美格鲁肽注射液的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| AU2002316811A1 (en) | 2001-06-28 | 2003-03-03 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| EP2932981B1 (en) | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
| CA2545034C (en) | 2003-11-20 | 2013-03-05 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| KR101340354B1 (ko) * | 2004-11-12 | 2013-12-11 | 노보 노르디스크 에이/에스 | 안정한 펩티드 제제 |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CA2646400A1 (en) * | 2006-04-14 | 2007-10-25 | Mannkind Corporation | Glucagon-like peptide 1(glp-1) pharmaceutical formulations |
| EP2121897A4 (en) | 2007-03-20 | 2010-03-31 | Nippon Kayaku Kk | METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL |
| JP2011504871A (ja) | 2007-06-01 | 2011-02-17 | ノボ・ノルデイスク・エー／エス | 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト |
| ES2672770T3 (es) | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivados del péptido-1 similar al glucagón y su uso farmacéutico |
| EP2190873B1 (en) | 2007-09-05 | 2015-07-22 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| PL2373681T3 (pl) | 2008-12-10 | 2017-07-31 | Glaxosmithkline Llc | Kompozycje farmaceutyczne albiglutydu |
| AU2010212823B2 (en) * | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| JP5411366B2 (ja) * | 2009-12-16 | 2014-02-12 | ノヴォ ノルディスク アー／エス | 二重アシル化ｇｌｐ−１誘導体 |
| ES2935300T3 (es) * | 2010-05-05 | 2023-03-03 | Boehringer Ingelheim Int | Combiterapia |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| WO2012080471A1 (en) | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| US20130035281A1 (en) * | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| US20140220134A1 (en) * | 2011-06-24 | 2014-08-07 | Astrazeneca Pharamceuticals LP | Method for treating diabetes with extended release formulation of glp-1 receptor agonists |
| SI2866825T1 (sl) | 2012-07-01 | 2020-07-31 | Novo Nordisk A/S | Uporaba dolgo delujočih peptidov GLP-1 |
-
2013
- 2013-06-21 SI SI201331733T patent/SI2866825T1/sl unknown
- 2013-06-21 PL PL20157813.5T patent/PL3689365T3/pl unknown
- 2013-06-21 MX MX2014014946A patent/MX366405B/es active IP Right Grant
- 2013-06-21 PL PL13737808.9T patent/PL2866825T3/pl unknown
- 2013-06-21 AU AU2013286177A patent/AU2013286177B2/en active Active
- 2013-06-21 MX MX2019008148A patent/MX376058B/es active IP Right Grant
- 2013-06-21 ES ES13737808T patent/ES2796839T3/es active Active
- 2013-06-21 PT PT137378089T patent/PT2866825T/pt unknown
- 2013-06-21 HR HRP20251088TT patent/HRP20251088T1/hr unknown
- 2013-06-21 RU RU2018117557A patent/RU2018117557A/ru unknown
- 2013-06-21 EP EP24175788.9A patent/EP4406593A3/en active Pending
- 2013-06-21 CA CA2877056A patent/CA2877056A1/en not_active Abandoned
- 2013-06-21 EP EP13737808.9A patent/EP2866825B1/en not_active Revoked
- 2013-06-21 ES ES20157813T patent/ES3041720T3/es active Active
- 2013-06-21 RS RS20200684A patent/RS60432B1/sr unknown
- 2013-06-21 HU HUE20157813A patent/HUE072859T2/hu unknown
- 2013-06-21 RS RS20250936A patent/RS67258B1/sr unknown
- 2013-06-21 EP EP20157813.5A patent/EP3689365B1/en active Active
- 2013-06-21 DK DK13737808.9T patent/DK2866825T3/da active
- 2013-06-21 RU RU2015101826A patent/RU2657573C2/ru active
- 2013-06-21 US US14/409,493 patent/US9764003B2/en active Active
- 2013-06-21 HR HRP20200889TT patent/HRP20200889T1/hr unknown
- 2013-06-21 BR BR112014032938A patent/BR112014032938A2/pt not_active Application Discontinuation
- 2013-06-21 HU HUE13737808A patent/HUE049152T2/hu unknown
- 2013-06-21 JP JP2015519000A patent/JP6059802B2/ja active Active
- 2013-06-21 WO PCT/EP2013/063004 patent/WO2014005858A1/en not_active Ceased
-
2014
- 2014-12-05 MX MX2020010693A patent/MX2020010693A/es unknown
-
2017
- 2017-07-21 US US15/656,042 patent/US10335462B2/en active Active
-
2018
- 2018-04-10 AU AU2018202504A patent/AU2018202504B2/en active Active
-
2020
- 2020-04-16 AU AU2020202573A patent/AU2020202573B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522573A5 (enExample) | ||
| MX2022004041A (es) | Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos. | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| PH12018501424B1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| GB2491328A (en) | Immediate/delayed drug delivery | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| JP2015110588A5 (enExample) | ||
| MX2013002244A (es) | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2012193216A5 (enExample) | ||
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| AU2018256619A1 (en) | Compounds for the treatment of obesity and methods of use thereof | |
| UA111599C2 (uk) | Композиція каспофунгіну | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| CN103748074B8 (zh) | 芳氧基喹啉类衍生物及其治疗用途 | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| TN2019000063A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| JP2015501832A5 (enExample) | ||
| WO2011119649A3 (en) | Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs | |
| WO2016072692A3 (ko) | 네크록스를 유효성분으로 함유하는 점막염 예방 또는 치료용 조성물 | |
| MX2018005345A (es) | Composiciones farmaceuticas de dimetil fumarato. | |
| JP2018043942A5 (enExample) | ||
| Sheehy | Ketamine/morphine |